Macrophage Anchoring Nanomedicine to Replace Steroids for Intra-articular Injection

巨噬细胞锚定纳米药物替代类固醇用于关节内注射

• 批准号: 10574148
• 负责人: Li Jin
• 金额: $ 17.77万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10574148
• 关键词: Address; Adult; Affect; Animals; Anti-Inflammatory Agents; Antiinflammatory Effect; Arthritis; Binding; Cartilage; Cartilage Matrix; Cell membrane; Charge; Chondrocytes; Confocal Microscopy; Degenerative polyarthritis; Disease; Dose; Drug or chemical Tissue Distribution; Drug usage; Electrostatics; Evaluation; FPR1 gene; Free Radical Scavenging; Fullerenes; Goals; Growth Factor; Harvest; Health Care Costs; Histology; Human; Hyaluronic Acid; Infiltration; Inflammation; Inflammation Mediators; Inflammatory; Injections; Injury; Interleukin-1 beta; Intra-Articular Injections; Joints; Knee; Knee Osteoarthritis; Knee joint; Macrophage; Measures; Mechanics; Medial meniscus structure; Mediator; Modality; Modeling; Monitor; Mus; Musculoskeletal Diseases; Neuropeptides; Nociception; Outcomes Research; Pain; Pathogenesis; Pathology; Penetration; Peptides; Permeability; Persons; Pharmaceutical Preparations; Phenotype; Property; Research; Spinal Ganglia; Steroids; Surface; Symptoms; Synovial Membrane; Therapeutic Effect; Time; Tissue Harvesting; Tissues; Translations; Treatment Efficacy; cartilage degradation; chondroprotection; clinical translation; clinically relevant; clinically significant; confocal imaging; efficacy evaluation; experimental study; fullerene C60; in vivo; in vivo imaging system; injured; joint destruction; joint inflammation; joint injury; knee pain; microCT; mouse model; multiplex assay; nanomedicine; nanoparticle; nanotechnology platform; novel; prevent; receptor; regenerative; synthetic peptide; therapeutic target; uptake

Osteoarthritis (OA) is the most common form of arthritis, affecting more than 32.5 million of US adults, with an associated healthcare cost at more than $185 billion annually. Current treatments for osteoarthritis address symptoms with limited disease-modifying potential. Inflammation is the key mediator of joint OA, making it the key target for osteoarthritis treatment. However, available anti-inflammatory drugs, such as steroids, are rapidly cleared from the joint. Fullerenes (C60) possess potent anti-inflammatory effects and are intrinsically superior to steroids and other molecules due to their long-lasting activity and cell membrane-penetrating capability. We recently developed a nanoplatform cFLFLF-C60 capable of suppressing inflammation and targeting macrophages, potentiating sustained joint retention and therapeutic effects. The goal of this project is to determine the therapeutic efficacy of the nanoplatform on OA and associated pain. Aim 1 will evaluate the efficacy of cFLFLF-C60 in human explant models of inflammatory OA. It will establish whether cFLFLF-C60 inhibits cartilage degradation and inflammation in human joint explants. Aim 2 will determine the sustained effects of treating OA and associated pain in a mouse model. It will elucidate the efficacy and time window of cFLFLF-C60 to modify cartilage degeneration and pain. This project represents a new and distinct direction for the field because it addresses the underlying pathogenesis of OA and sustained joint delivery.

骨关节炎（OA）是最常见的关节炎形式，影响超过3250万美国成年人，其中 相关的医疗费用每年超过1850亿美元。骨关节炎的当前治疗方法 具有有限的疾病改善潜力的症状。炎症是关节骨性关节炎的关键介质，使其成为关节炎的主要发病机制。 骨关节炎治疗关键目标。然而，可用的抗炎药，如类固醇， 从监狱里出来了富勒烯（C60）具有有效的抗炎作用，本质上上级 类固醇和其他分子，因为它们具有持久的活性和细胞膜穿透能力。我们 最近开发了一种纳米平台cFLFLF-C60，能够抑制炎症和靶向 巨噬细胞，增强持续的关节保留和治疗效果。该项目的目标是 确定纳米平台对OA和相关疼痛的治疗功效。目标1将评估 cFLFLF-C60在炎性OA的人外植体模型中的功效。它将确定cFLFLF-C60是否抑制 软骨退化和炎症。目标2将决定 在小鼠模型中治疗OA和相关疼痛。它将阐明cFLFLF-C60的疗效和时间窗 来改善软骨退化和疼痛该项目代表了该领域的一个新的和独特的方向 因为它解决了骨关节炎的潜在发病机制和持续的关节输送。